Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge

Abstract The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis and haemostasis Jg. 120; H. 6; S. 949 - 956
Hauptverfasser:	Violi, Francesco, Pastori, Daniele, Cangemi, Roberto, Pignatelli, Pasquale, Loffredo, Lorenzo
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Stuttgart · New York Georg Thieme Verlag KG 01.06.2020
Schlagworte:	Algorithms Betacoronavirus Cardiology Coronavirus Infections - blood Coronavirus Infections - complications COVID-19 Fibrin Fibrinogen Degradation Products - analysis Fibrinolytic Agents - therapeutic use Humans Liver Failure - therapy Pandemics Partial Thromboplastin Time Platelet Count Pneumonia, Viral - blood Pneumonia, Viral - complications Prothrombin Time Review Article Risk SARS-CoV-2 Thrombophilia - prevention & control Thrombophilia - therapy Thrombosis - prevention & control Thrombosis - therapy Treatment Outcome hypercoagulability thrombosis infectious diseases
ISSN:	0340-6245, 2567-689X, 2567-689X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!